vs

Side-by-side financial comparison of PRECISION BIOSCIENCES INC (DTIL) and NATIONAL RESEARCH CORP (NRC). Click either name above to swap in a different company.

NATIONAL RESEARCH CORP is the larger business by last-quarter revenue ($35.2M vs $34.2M, roughly 1.0× PRECISION BIOSCIENCES INC). PRECISION BIOSCIENCES INC runs the higher net margin — 58.9% vs 5.1%, a 53.8% gap on every dollar of revenue. On growth, PRECISION BIOSCIENCES INC posted the faster year-over-year revenue change (5261.1% vs -4.6%). NATIONAL RESEARCH CORP produced more free cash flow last quarter ($6.1M vs $-11.3M). Over the past eight quarters, PRECISION BIOSCIENCES INC's revenue compounded faster (39.5% CAGR vs -0.2%).

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.

DTIL vs NRC — Head-to-Head

Bigger by revenue
NRC
NRC
1.0× larger
NRC
$35.2M
$34.2M
DTIL
Growing faster (revenue YoY)
DTIL
DTIL
+5265.8% gap
DTIL
5261.1%
-4.6%
NRC
Higher net margin
DTIL
DTIL
53.8% more per $
DTIL
58.9%
5.1%
NRC
More free cash flow
NRC
NRC
$17.3M more FCF
NRC
$6.1M
$-11.3M
DTIL
Faster 2-yr revenue CAGR
DTIL
DTIL
Annualised
DTIL
39.5%
-0.2%
NRC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DTIL
DTIL
NRC
NRC
Revenue
$34.2M
$35.2M
Net Profit
$20.1M
$1.8M
Gross Margin
Operating Margin
36.6%
13.3%
Net Margin
58.9%
5.1%
Revenue YoY
5261.1%
-4.6%
Net Profit YoY
213.5%
-72.6%
EPS (diluted)
$2.62
$49.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DTIL
DTIL
NRC
NRC
Q4 25
$34.2M
$35.2M
Q3 25
$13.0K
$34.6M
Q2 25
$18.0K
$34.0M
Q1 25
$29.0K
$33.6M
Q4 24
$638.0K
$36.9M
Q3 24
$576.0K
$35.8M
Q2 24
$49.9M
$35.0M
Q1 24
$17.6M
$35.3M
Net Profit
DTIL
DTIL
NRC
NRC
Q4 25
$20.1M
$1.8M
Q3 25
$-21.8M
$4.1M
Q2 25
$-23.5M
$-106.0K
Q1 25
$-20.6M
$5.8M
Q4 24
$6.6M
Q3 24
$-16.4M
$5.7M
Q2 24
$32.7M
$6.2M
Q1 24
$8.6M
$6.4M
Operating Margin
DTIL
DTIL
NRC
NRC
Q4 25
36.6%
13.3%
Q3 25
-158976.9%
22.4%
Q2 25
-121538.9%
4.7%
Q1 25
-76248.3%
25.6%
Q4 24
26.0%
Q3 24
-3693.6%
22.3%
Q2 24
48.4%
25.3%
Q1 24
-23.8%
24.8%
Net Margin
DTIL
DTIL
NRC
NRC
Q4 25
58.9%
5.1%
Q3 25
-167476.9%
11.9%
Q2 25
-130666.7%
-0.3%
Q1 25
-70913.8%
17.2%
Q4 24
17.8%
Q3 24
-2851.6%
15.9%
Q2 24
65.6%
17.6%
Q1 24
48.8%
18.0%
EPS (diluted)
DTIL
DTIL
NRC
NRC
Q4 25
$2.62
$49.58
Q3 25
$-1.84
$0.18
Q2 25
$-2.13
$-0.01
Q1 25
$-2.21
$0.25
Q4 24
$0.27
Q3 24
$-2.25
$0.24
Q2 24
$4.67
$0.26
Q1 24
$1.70
$0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DTIL
DTIL
NRC
NRC
Cash + ST InvestmentsLiquidity on hand
$115.6M
$4.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$92.2M
$14.0M
Total Assets
$154.4M
$134.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DTIL
DTIL
NRC
NRC
Q4 25
$115.6M
$4.1M
Q3 25
$44.9M
$2.2M
Q2 25
$62.2M
$5.3M
Q1 25
$77.2M
$2.5M
Q4 24
$86.3M
$4.2M
Q3 24
$101.2M
$3.5M
Q2 24
$123.6M
$485.0K
Q1 24
$137.8M
$1.7M
Total Debt
DTIL
DTIL
NRC
NRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$48.7M
Q2 24
$33.3M
Q1 24
$35.2M
Stockholders' Equity
DTIL
DTIL
NRC
NRC
Q4 25
$92.2M
$14.0M
Q3 25
$16.6M
$14.3M
Q2 25
$34.1M
$21.3M
Q1 25
$49.3M
$29.7M
Q4 24
$56.4M
$31.3M
Q3 24
$64.9M
$34.6M
Q2 24
$74.7M
$40.2M
Q1 24
$37.2M
$36.9M
Total Assets
DTIL
DTIL
NRC
NRC
Q4 25
$154.4M
$134.9M
Q3 25
$93.5M
$135.7M
Q2 25
$108.9M
$141.4M
Q1 25
$124.4M
$135.2M
Q4 24
$136.4M
$132.5M
Q3 24
$153.3M
$131.8M
Q2 24
$165.8M
$119.1M
Q1 24
$184.7M
$120.9M
Debt / Equity
DTIL
DTIL
NRC
NRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
1.41×
Q2 24
0.83×
Q1 24
0.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DTIL
DTIL
NRC
NRC
Operating Cash FlowLast quarter
$-11.3M
$7.2M
Free Cash FlowOCF − Capex
$-11.3M
$6.1M
FCF MarginFCF / Revenue
-32.9%
17.2%
Capex IntensityCapex / Revenue
0.1%
3.2%
Cash ConversionOCF / Net Profit
-0.56×
3.99×
TTM Free Cash FlowTrailing 4 quarters
$15.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DTIL
DTIL
NRC
NRC
Q4 25
$-11.3M
$7.2M
Q3 25
$-15.3M
$13.8M
Q2 25
$-20.3M
$-1.1M
Q1 25
$-19.1M
$6.6M
Q4 24
$-58.4M
$6.4M
Q3 24
$-5.9M
$9.4M
Q2 24
$-14.9M
$6.8M
Q1 24
$-19.0M
$12.0M
Free Cash Flow
DTIL
DTIL
NRC
NRC
Q4 25
$-11.3M
$6.1M
Q3 25
$10.2M
Q2 25
$-20.3M
$-4.1M
Q1 25
$-19.1M
$3.7M
Q4 24
$-58.7M
$1.9M
Q3 24
$-6.0M
$7.8M
Q2 24
$-14.9M
$1.5M
Q1 24
$-19.1M
$7.9M
FCF Margin
DTIL
DTIL
NRC
NRC
Q4 25
-32.9%
17.2%
Q3 25
29.4%
Q2 25
-112627.8%
-12.2%
Q1 25
-65917.2%
10.9%
Q4 24
-9199.8%
5.2%
Q3 24
-1033.2%
21.8%
Q2 24
-29.9%
4.3%
Q1 24
-108.4%
22.4%
Capex Intensity
DTIL
DTIL
NRC
NRC
Q4 25
0.1%
3.2%
Q3 25
0.0%
10.4%
Q2 25
11.1%
8.8%
Q1 25
220.7%
8.9%
Q4 24
39.2%
12.0%
Q3 24
6.8%
4.5%
Q2 24
0.1%
15.0%
Q1 24
0.5%
11.7%
Cash Conversion
DTIL
DTIL
NRC
NRC
Q4 25
-0.56×
3.99×
Q3 25
3.34×
Q2 25
Q1 25
1.15×
Q4 24
0.97×
Q3 24
1.66×
Q2 24
-0.45×
1.10×
Q1 24
-2.21×
1.89×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons